Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders.
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
pmc-release:
26
04
2024
medline:
9
6
2023
pubmed:
26
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Physical health and chronic medical comorbidities are underestimated, inadequately treated, and often overlooked in psychiatry. A multiorgan, systemwide characterization of brain and body health in neuropsychiatric disorders may enable systematic evaluation of brain-body health status in patients and potentially identify new therapeutic targets. To evaluate the health status of the brain and 7 body systems across common neuropsychiatric disorders. Brain imaging phenotypes, physiological measures, and blood- and urine-based markers were harmonized across multiple population-based neuroimaging biobanks in the US, UK, and Australia, including UK Biobank; Australian Schizophrenia Research Bank; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer's Disease Neuroimaging Initiative; Prospective Imaging Study of Ageing; Human Connectome Project-Young Adult; and Human Connectome Project-Aging. Cross-sectional data acquired between March 2006 and December 2020 were used to study organ health. Data were analyzed from October 18, 2021, to July 21, 2022. Adults aged 18 to 95 years with a lifetime diagnosis of 1 or more common neuropsychiatric disorders, including schizophrenia, bipolar disorder, depression, generalized anxiety disorder, and a healthy comparison group were included. Deviations from normative reference ranges for composite health scores indexing the health and function of the brain and 7 body systems. Secondary outcomes included accuracy of classifying diagnoses (disease vs control) and differentiating between diagnoses (disease vs disease), measured using the area under the receiver operating characteristic curve (AUC). There were 85 748 participants with preselected neuropsychiatric disorders (36 324 male) and 87 420 healthy control individuals (40 560 male) included in this study. Body health, especially scores indexing metabolic, hepatic, and immune health, deviated from normative reference ranges for all 4 neuropsychiatric disorders studied. Poor body health was a more pronounced illness manifestation compared to brain changes in schizophrenia (AUC for body = 0.81 [95% CI, 0.79-0.82]; AUC for brain = 0.79 [95% CI, 0.79-0.79]), bipolar disorder (AUC for body = 0.67 [95% CI, 0.67-0.68]; AUC for brain = 0.58 [95% CI, 0.57-0.58]), depression (AUC for body = 0.67 [95% CI, 0.67-0.68]; AUC for brain = 0.58 [95% CI, 0.58-0.58]), and anxiety (AUC for body = 0.63 [95% CI, 0.63-0.63]; AUC for brain = 0.57 [95% CI, 0.57-0.58]). However, brain health enabled more accurate differentiation between distinct neuropsychiatric diagnoses than body health (schizophrenia-other: mean AUC for body = 0.70 [95% CI, 0.70-0.71] and mean AUC for brain = 0.79 [95% CI, 0.79-0.80]; bipolar disorder-other: mean AUC for body = 0.60 [95% CI, 0.59-0.60] and mean AUC for brain = 0.65 [95% CI, 0.65-0.65]; depression-other: mean AUC for body = 0.61 [95% CI, 0.60-0.63] and mean AUC for brain = 0.65 [95% CI, 0.65-0.66]; anxiety-other: mean AUC for body = 0.63 [95% CI, 0.62-0.63] and mean AUC for brain = 0.66 [95% CI, 0.65-0.66). In this cross-sectional study, neuropsychiatric disorders shared a substantial and largely overlapping imprint of poor body health. Routinely monitoring body health and integrated physical and mental health care may help reduce the adverse effect of physical comorbidity in people with mental illness.
Identifiants
pubmed: 37099313
pii: 2804355
doi: 10.1001/jamapsychiatry.2023.0791
pmc: PMC10134046
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-576Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Références
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
Lancet Neurol. 2014 Aug;13(8):788-94
pubmed: 25030513
BMJ Open. 2015 Dec 15;5(12):e009010
pubmed: 26671955
World Psychiatry. 2017 Feb;16(1):1-2
pubmed: 28127919
Neuropsychopharmacology. 2022 Apr;47(5):1071-1080
pubmed: 35058584
Psychol Med. 2018 Dec;48(16):2693-2701
pubmed: 29490716
Int J Nurs Stud. 2007 Mar;44(3):457-66
pubmed: 17007859
Heart. 2007 Oct;93(10):1256-62
pubmed: 17344333
Ann Gen Psychiatry. 2018 May 04;17:16
pubmed: 29755578
Lancet. 2012 Feb 25;379(9817):721-8
pubmed: 22265699
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Psychosomatics. 2010 Nov-Dec;51(6):458-65
pubmed: 21051676
Neurology. 2022 Aug 9;99(6):e574-e582
pubmed: 35831178
J Crohns Colitis. 2021 Nov 8;15(11):1824-1836
pubmed: 33640971
Biol Psychiatry. 2016 Oct 1;80(7):552-61
pubmed: 26927419
Nat Rev Endocrinol. 2023 Jan;19(1):10-27
pubmed: 36224493
Br J Gen Pract. 1998 Jul;48(432):1415-6
pubmed: 9800401
PLoS One. 2014 Nov 04;9(11):e111682
pubmed: 25369130
Neuroimage. 2018 Feb 15;167:104-120
pubmed: 29155184
JAMA Psychiatry. 2015 Apr;72(4):305-15
pubmed: 25651064
Mol Psychiatry. 2018 Apr;23(4):932-942
pubmed: 28461699
Acta Psychiatr Scand. 2015 Aug;132(2):144-57
pubmed: 25943829
Mol Psychiatry. 2017 Jun;22(6):900-909
pubmed: 27137745
Nat Protoc. 2022 Jul;17(7):1711-1734
pubmed: 35650452
Pharmacol Ther. 2010 Jan;125(1):169-79
pubmed: 19931306
World Psychiatry. 2017 Oct;16(3):308-315
pubmed: 28941119
Nature. 2022 Apr;604(7906):525-533
pubmed: 35388223
Schizophr Bull. 2013 Mar;39(2):295-305
pubmed: 22927670
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
JAMA Psychiatry. 2022 Jul 1;79(7):667-676
pubmed: 35507366
Arch Toxicol. 2021 Mar;95(3):767-789
pubmed: 33398419
Brain Struct Funct. 2008 Sep;213(1-2):93-118
pubmed: 18704495
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):657-64
pubmed: 12438466
JAMA. 1990 Nov 21;264(19):2511-8
pubmed: 2232018
Int Rev Neurobiol. 2020;152:41-69
pubmed: 32451000
Chronic Stress (Thousand Oaks). 2017 Jun 8;1:
pubmed: 29503978
Diabetes Care. 2002 Dec;25(12):2165-71
pubmed: 12453955
Acta Psychiatr Scand. 2008 Sep;118(3):169-71
pubmed: 18699951
Nat Neurosci. 2019 Oct;22(10):1617-1623
pubmed: 31551603
World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):26-38
pubmed: 28217372
Ageing Res Rev. 2020 Dec;64:101045
pubmed: 32171784
JAMA Psychiatry. 2022 Sep 1;79(9):879-888
pubmed: 35895072
JAMA Psychiatry. 2016 Feb;73(2):150-8
pubmed: 26719969
Biol Psychiatry. 2021 Nov 1;90(9):643-651
pubmed: 34344534
J Neurosci. 2003 Feb 1;23(3):994-1005
pubmed: 12574429
Future Sci OA. 2015 Nov 01;1(3):FSO23
pubmed: 28031896
Biol Psychiatry. 2023 Jan 15;93(2):125-136
pubmed: 36335069
Biol Psychiatry. 2019 Jan 1;85(1):35-48
pubmed: 30122288
Diabet Med. 2018 Jun;35(6):677-693
pubmed: 29460506
Lancet. 2012 Jul 14;380(9837):110
pubmed: 22794246
Transl Psychiatry. 2021 Oct 1;11(1):502
pubmed: 34599145
J Affect Disord. 2016 May;195:185-90
pubmed: 26896812
Lancet Psychiatry. 2016 Jan;3(1):40-48
pubmed: 26620388
Clin Psychopharmacol Neurosci. 2019 May 31;17(2):279-287
pubmed: 30905128
J Affect Disord. 2014 Sep;166:22-9
pubmed: 25012406
Lancet Psychiatry. 2022 Sep;9(9):725-735
pubmed: 35871794
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Lancet Psychiatry. 2016 Feb;3(2):171-8
pubmed: 26851330
Psychiatry (Edgmont). 2006 Oct;3(10):57-63
pubmed: 20877548
World Psychiatry. 2015 Oct;14(3):339-47
pubmed: 26407790
Soc Psychiatry Psychiatr Epidemiol. 2017 Dec;52(12):1451-1461
pubmed: 29080941
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Curr Neuropharmacol. 2015;13(4):494-504
pubmed: 26412069
Clin Epidemiol. 2018 Apr 16;10:421-429
pubmed: 29713199
Can J Diabetes. 2015 Aug;39(4):266-72
pubmed: 25773933
Arch Gen Psychiatry. 2010 Oct;67(10):1002-11
pubmed: 20921116
J Clin Psychiatry. 2004 May;65(5):634-51, quiz 730
pubmed: 15163249